Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Committee advances narrower pilot for psychedelic-assisted therapy despite mixed public testimony
Summary
Senate Bill 248, which narrows last year's pilot for psychedelic-assisted therapies to a small set of providers and includes provisions to align state scheduling with FDA changes, was favorably recommended 5–0 after extended testimony from clinicians, researchers, veterans advocates and advocacy groups.
Senate Bill 248, as amended by substitute 1 and presented by Senator Cullimore, would narrow a previously enacted pilot program for psychedelic-assisted therapy by restricting participation to a limited set of qualified providers and by allowing the state to reschedule substances in alignment with FDA actions. The Senate Health and Human Services Committee unanimously advanced the substitute on Feb. 28.
Senator Cullimore said the original statute from the prior year authorized a narrowly scoped pilot but "nothing has really taken off the ground" because of difficulties sourcing controlled substances for clinical use. He said the substitute tightens eligibility to a palliative cancer-treatment center with established expertise and a licensed psychiatrist experienced in administering drugs under clinical trials, and adds language allowing the state to reschedule if the FDA reschedules.
Testimony from the public…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
